BeiGene Announces Clinical Data on Tislelizumab and Zanubrutinib to be Presented at the 24th Congress of the European Hematology Association
CAMBRIDGE, Mass. and BEIJING, China, May 16, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced data presentations on its investigational anti-PD-1 antibody tislelizumab and its investigational BTK inhibitor zanubrutinib from four posters at the 24th Congress of the European Hematology Association (EHA), taking place June 13-16, 2019 in Amsterdam.
Title: Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a Phase 2 study Abstract Code: PF469 Session Title: Hodgkin lymphoma – Clinical Date: Friday, June 14 Time: 17:30 – 19:00 (CEST) Lead Author: Yuqin Song, M.D., Ph.D.
Title: Major responses in MYD88 wildtype (MYD88WT) Waldenström Macroglobulinemia (WM) patients treated with Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) Abstract Code: PF487 Session Title: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical Date: Friday, June 14 Time: 17:30 – 19:00 (CEST) Lead Author: Meletios A. Dimopoulos, M.D.
Updated safety and efficacy data in a Phase 1/2 trial of patients with Waldenström Title: Macroglobulinaemia (WM) treated with the Bruton Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111) Abstract Code: PF481 Session Title: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical Date: Friday, June 14 Time: 17:30 – 19:00 (CEST) Lead Author: Judith Trotman, MBChB, FRACP, FRCPA
Title: Pooled analysis of safety data from monotherapy studies of the Bruton Tyrosine Kinase (BTK) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies Abstract Code: PS1159 Session Title: Chronic lymphocytic leukemia and related disorders – Clinical Date: Saturday, June 15 Time: 17:30 – 19:00 (CEST) Lead Author: Constantine S. Tam, M.D.
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,400 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i
Investor Contact Media ContactCraig West Liza Heapes+1 857-302-5189 +1 email@example.com firstname.lastname@example.org
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation